Stealth BioTherapeutics
Stealth BioTherapeutics develops therapies for mitochondrial dysfunction related to genetic diseases and aging, with a focus on elamipretide and SBT-272 in clinical studies.
Services
Stealth BioTherapeutics offers an Expanded Access Program that provides investigational drugs to patients with serious or life-threatening conditions who are not eligible for clinical trials. This initiative helps ensure that patients in urgent need have access to cutting-edge therapies. The company also supports educational programs and initiatives aimed at providing healthcare providers and patient communities with valuable information on disease awareness and therapeutic management.
Therapies for Mitochondrial Dysfunction
Stealth BioTherapeutics focuses on developing therapies for mitochondrial dysfunction, which is implicated in various genetic mitochondrial diseases and common diseases of aging. Their efforts aim to address the root causes of these conditions through innovative treatments that target mitochondrial health and function.
Clinical Studies
Stealth BioTherapeutics is actively investigating the drug elamipretide in late-stage clinical studies for a range of conditions including ophthalmic diseases, rare neuromuscular disorders, and rare cardiomyopathies. These studies are critical to advancing understanding and treatment options for these challenging medical issues.
SBT-272 for Neurological Diseases
The company is evaluating SBT-272, a second-generation clinical-stage candidate, for the treatment of rare neurological diseases such as amyotrophic lateral sclerosis (ALS). This research is part of their broader commitment to addressing unmet medical needs in the field of neurodegenerative disorders.
Location
Stealth BioTherapeutics is headquartered at 123 Highland Ave, Suite 201, Needham, MA 02494. This location serves as the central hub for their research, development, and operational activities.